REPORTS EPS OF $0.38 AND ADJUSTED EPS OF $0.42 ON REVENUES OF $141 MILLION
COMPLETES REFINANCING OF CREDIT FACILITIES
NASHVILLE, Tenn., April 27, 2017 (GLOBE NEWSWIRE) — Tivity Health, Inc. (NASDAQ:TVTY) today announced financial results for the first quarter ended March 31, 2017.
First-Quarter 2017 Financial Highlights
- Revenues increased by 11.9% to $141.0 million compared with $126.0 million for the first quarter of 2016, driven by growth in all three of the Company’s product lines.
- Net income from continuing operations was $15.5 million compared with $19.2 million for the first quarter of 2016. Results for the first quarter of 2017 include an effective income tax rate of 37.7% and the impact of pre-tax business separation and restructuring charges totaling $2.4 million. Results for the first quarter of 2016 include an effective income tax rate of 0%, due to tax benefits derived from utilizing net operating loss carryforwards from 2015 that were previously subject to a valuation allowance, as well as pre-tax restructuring charges of $39 thousand.
- Adjusted net income from continuing operations, excluding business separation and restructuring charges, was $16.9 million for the first quarter of 2017 and $19.2 million for the first quarter of 2016. For illustration, had net income from continuing operations for the first quarter of 2016 been subject to a normalized tax rate of 40.0%, it would have been $11.5 million. See pages 10-12 for a reconciliation of non-GAAP financial measures.
- Net income from continuing operations per diluted share was $0.38 compared with $0.52 for the first quarter of 2016, and adjusted net income from continuing operations per diluted share was $0.42 compared with $0.52 for the first quarter of 2016. For illustration, had net income from continuing operations for the first quarter of 2016 been subject to a normalized tax rate of 40.0%, net income from continuing operations per diluted share would have been $0.31. Weighted average diluted shares outstanding increased 10.0% for the first quarter of 2017 from the first quarter of 2016.
- Adjusted EBITDA, which excluded business separation and restructuring expenses, increased 26.3% to $31.8 million compared with $25.2 million for the first quarter of 2016. Adjusted EBITDA margin increased to 22.6% for the first quarter of 2017 compared with 20.0% for the first quarter of 2016. See pages 10-12 for a reconciliation of non-GAAP financial measures.
- Funded debt was $214.8 million at the end of the first quarter of 2017, and the ratio of total debt to trailing 12 months EBITDA, as calculated under the Company’s then effective credit facility, improved to 1.8 from 1.9 at the end of 2016.
| TIVITY HEALTH, INC. | |||||||||
| Financial Highlights | |||||||||
| (Dollars in millions, except per-share data) | |||||||||
| See pages 10-12 for a reconciliation of non-GAAP financial measures | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2017 | 2016 | ||||||||
| Revenues | $ | 141.0 | $ | 126.0 | |||||
| Per diluted share: | |||||||||
| Net income from continuing operations, GAAP basis | $ | 0.38 | $ | 0.52 | |||||
| Business separation expense | 0.02 | – | |||||||
| Restructuring charges | 0.01 | – | |||||||
| Adjusted net income from continuing operations, non-GAAP basis1 | $ | 0.42 | $ | 0.52 | |||||
| Weighted average diluted common shares outstanding (in thousands) | 40,541 | 36,861 | |||||||
| 1 Figures may not add due to rounding. | |||||||||
“We are pleased with our first-quarter financial results,” said Donato Tramuto, Tivity Health’s Chief Executive Officer. “Due to the strength of this performance and the visibility it gives us for the rest of 2017, we have increased our financial guidance for the full year.
“We are also pleased to announce a three-year renewal of our SilverSneakers® contract with UnitedHealth Group, continuing a 20-year relationship with a partner who shares our commitment to active lifestyles. This renewal and many other renewals we have achieved to date are a clear indication of the value of both our brand and the services provided to our customers and their members through the SilverSneakers program.”
Glenn Hargreaves, Tivity Health’s Interim Chief Financial Officer, added, “During the first quarter, we essentially completed our restructuring and business separation initiatives and realized cost savings that annualize to approximately $15 million from the restructuring, which contributed to expanding our adjusted EBITDA margin.
“Tivity Health’s cash flow from operations for the first quarter of 2017 totaled $3.0 million. First-quarter cash flow reflects our expected seasonality due to the payment of the 2016 colleague bonus and the full-year 2016 401(k) Plan matching contributions. Cash flow for the first quarter was also reduced due to the timing of payments from two long-term customers, which have since been paid. Our guidance for free cash flow for the full year remains unchanged.”
Completes Refinancing of Credit Facilities
On April 21, 2017, Tivity Health completed the refinancing of its senior credit facilities. The new facilities include a $100 million revolving credit facility, a $70 million term loan A facility, a $150 million delayed draw term loan facility and an uncommitted incremental accordion facility of $100 million. Proceeds of the revolving loans and delayed draw term loans may be used to repay outstanding indebtedness, including amounts payable upon any conversion of the Company’s $150 million cash convertible senior notes due 2018. As previously disclosed, the stock trading price threshold requirement for convertibility of the senior notes was met in the first quarter of 2017. Consequently, the senior notes are convertible into cash at the option of the holder during the period of April 1, 2017 through June 30, 2017. As a result, and even if holders do not elect to convert, applicable accounting rules require Tivity Health to reclassify the senior notes as a current rather than long-term liability at March 31, 2017.
Increases 2017 Financial Guidance
Tivity Health announced today that, based on first-quarter results and the Company’s outlook for the remainder of 2017, financial guidance for 2017 has been modified as follows:
- revenues in a range of $550 million to $558 million, compared with the previous range of $540 million to $550 million;
- adjusted EBITDA in a range of $119 million to $123 million, compared with the previous range of $116 million to $120 million; and
- adjusted earnings per diluted share in a range of $1.50 to $1.58, compared with the previous range of $1.44 to $1.52.
The guidance for adjusted EBITDA and adjusted earnings per diluted share reflects the exclusion of pre-tax restructuring and business separation expenses totaling $2.4 million that were incurred in the first quarter of 2017. See page 12 for a reconciliation of adjusted earnings per diluted share guidance to earnings per diluted share guidance. The Company does not provide a reconciliation of adjusted EBITDA guidance because certain information required for such reconciliation is not determinable with reasonable certainty.
This guidance for 2017 includes:
- depreciation and amortization expense of approximately $3 million;
- a federal income tax rate for the remainder of the year of approximately 39%;
- weighted average diluted shares outstanding of approximately 41 million for the full year;
- free cash flow of $90 million to $95 million; and
- capital expenditures of $8 million to $10 million.
Summary
Tramuto concluded, “Our first-quarter performance provides further evidence of our ability to fiercely execute on our plan, to produce profitable growth serving markets that have compelling long-term growth dynamics, and to deliver value to our customers and shareholders. Through our A-B-C-D strategy, the goals of which are to (A) add new members in our three existing networks – SilverSneakers®, Prime® Fitness and WholeHealth LivingTM; (B) build engagement and participation among our current eligible members; (C) collaborate with partners to add new products and services that will leverage the value of our brand; and (D) deepen relationships with our partners and their instructors within our national network, we believe we are well positioned to strengthen our market leadership position in serving the age 50-plus market. We are actively developing and testing a variety of innovative initiatives designed to increase the number of active members and the frequency of their participation. With SilverSneakers as the leading, trusted brand in the market, Tivity Health intends to help our eligible members live their best lives with vitality, dignity, and purpose.”
Conference Call
Tivity Health will hold a conference call to discuss this release today at 5:00 p.m. Eastern Time. Investors will have the opportunity to listen to the conference call live over the Internet by going to www.tivityhealth.com and clicking Investors at least 15 minutes early to register, download and install any necessary audio software. Presentation materials related to the conference call may also be accessed by going to www.tivityhealth.com and clicking Investors. For those who cannot listen to the live broadcast, a telephonic replay will be available for one week at 719-457-0820, code 2140921, and the replay will also be available on the Company’s web site for the next 12 months.
Safe Harbor Provisions
This press release contains forward-looking statements, including our guidance and financial expectations for future periods, which are based upon current expectations, involve a number of risks and uncertainties and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding the intent, belief or expectations of the Company, including, without limitation, all statements regarding the Company’s future earnings, revenues and results of operations. Those forward-looking statements are subject to the finalization of the Company’s quarterly financial accounting procedures and may be affected by certain risks and uncertainties, including, but not limited to:
- the risks associated with recent changes in the Company’s senior management team;
- the Company’s ability to sign and implement new contracts for its solutions;
- the Company’s ability to accurately forecast the costs required to successfully implement new contracts;
- the Company’s ability to anticipate change and respond to emerging trends for healthcare and the impact of the same on demand for the Company’s products and services;
- the Company’s ability to develop new products;
- the Company’s ability to anticipate and respond to strategic changes, opportunities and emerging trends in the Company’s industry and/or business and to accurately forecast the related impact on the Company’s revenues and earnings;
- the Company’s ability to renew and/or maintain contracts with its customers under existing terms or restructure these contracts on terms that would not have a material negative impact on the Company’s results of operations;
- the Company’s ability to accurately forecast the Company’s revenues, margins, earnings and net income, as well as any potential charges that the Company may incur as a result of changes in its business and leadership;
- the Company’s ability and/or the ability of its customers to enroll participants and to accurately forecast their level of enrollment and participation in the Company’s programs in a manner and within the timeframe anticipated by the Company;
- the risks associated with deriving a significant concentration of revenues from a limited number of customers;
- the risks associated with changes in macroeconomic conditions;
- the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of our information systems or those of third-party vendors or other service providers, which may result in unauthorized access by third parties to customer, employee or Company information or protected health information and lead to enforcement actions, fines and other litigation against the Company;
- the Company’s ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed the Company’s resources;
- the Company’s ability to service its debt and remain in compliance with its debt covenants;
- the Company’s ability to obtain adequate financing to provide the capital that may be necessary to support its operations;
- the ability of the Company’s customers to maintain the number of covered lives enrolled in the plans during the terms of its agreements;
- counterparty risk associated with the Company’s cash convertible notes hedges;
- the risks associated with valuation of the cash convertible notes hedges and the cash conversion derivative, which may result in volatility to the Company’s consolidated statements of comprehensive income (loss) if these transactions do not completely offset one another;
- the impact of any new or proposed legislation, regulations and interpretations relating to Medicare or Medicare Advantage;
- the impact of litigation involving the Company and/or its subsidiaries;
- the impact on the Company’s operations and/or demand for its services of future state and federal legislation and regulations applicable to the Company’s business, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010;
- current geopolitical turmoil, the continuing threat of domestic or international terrorism, and the potential emergence of a health pandemic or infectious disease outbreak; and
- other risks detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and other filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update or revise any such forward-looking statements.
About Tivity Health
Tivity Health, Inc. is a leading provider of fitness and health improvement programs, with strong capabilities in developing and managing network solutions. Through its existing three networks, SilverSneakers® – the nation’s leading fitness program for older adults, Prime® Fitness and WholeHealth Living™, Tivity Health is focused on targeted population health for those 50 and over. With more than 14.5 million Americans eligible for SilverSneakers, over 10,000 fitness centers in the Prime Fitness Network, and more than 25 years of clinical and operational expertise in managing specialty health benefits and networks, including chiropractic services, physical therapy, occupational therapy, speech therapy, acupuncture, massage and complementary and alternative medicine (CAM) services, the Company touches millions of consumers across the country and works directly with hundreds of healthcare practitioners and many of the nation’s largest payers and employers. Learn more at www.tivityhealth.com.
| TIVITY HEALTH, INC. | |||||||||
| CONSOLIDATED BALANCE SHEETS | |||||||||
| (In thousands) | |||||||||
| (Unaudited) | |||||||||
| ASSETS | |||||||||
| March 31, 2017 | December 31, 2016 | ||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 664 | $ | 1,602 | |||||
| Accounts receivable, net | 66,942 | 50,424 | |||||||
| Prepaid expenses | 3,662 | 3,409 | |||||||
| Other current assets | 2,288 | 2,250 | |||||||
| Cash convertible notes hedges, current | 82,445 | — | |||||||
| Income taxes receivable | — | 426 | |||||||
| Total current assets | 156,001 | 58,111 | |||||||
| Property and equipment: | |||||||||
| Leasehold improvements | 10,144 | 10,144 | |||||||
| Computer equipment and related software | 23,404 | 23,024 | |||||||
| Furniture and office equipment | 8,670 | 8,670 | |||||||
| Capital projects in process | 2,506 | 2,079 | |||||||
| 44,724 | 43,917 | ||||||||
| Less accumulated depreciation | (36,379 | ) | (35,586 | ) | |||||
| 8,345 | 8,331 | ||||||||
| Other assets | 6,646 | 6,688 | |||||||
| Cash convertible notes hedges, long-term | — | 48,361 | |||||||
| Long-term deferred tax asset | 57,129 | 59,562 | |||||||
| Intangible assets, net | 29,049 | 29,049 | |||||||
| Goodwill, net | 334,680 | 334,680 | |||||||
| Total assets | $ | 591,850 | $ | 544,782 | |||||
| TIVITY HEALTH, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (In thousands, except share and per share data) | ||||||||
| (Unaudited) | ||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| March 31, 2017 | December 31, 2016 | |||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 27,577 | $ | 26,029 | ||||
| Accrued salaries and benefits | 7,999 | 18,686 | ||||||
| Accrued liabilities | 38,215 | 33,623 | ||||||
| Other current liabilities | 364 | 397 | ||||||
| Cash conversion derivative, current | 82,445 | — | ||||||
| Current portion of long-term debt | 147,102 | 46,046 | ||||||
| Current portion of long-term liabilities | 5,831 | 7,582 | ||||||
| Total current liabilities | 309,533 | 132,363 | ||||||
| Long-term debt | 60,196 | 164,297 | ||||||
| Cash conversion derivative, long-term | — | 48,361 | ||||||
| Other long-term liabilities | 8,149 | 10,463 | ||||||
| Stockholders’ equity: | ||||||||
| Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding | — | — | ||||||
| Common stock $.001 par value, 120,000,000 shares authorized, 39,188,902 and 38,933,580 shares outstanding | 39 | 39 | ||||||
| Additional paid-in capital | 344,108 | 341,270 | ||||||
| Accumulated deficit | (97,602 | ) | (119,327 | ) | ||||
| Treasury stock, at cost, 2,254,953 shares in treasury | (28,182 | ) | (28,182 | ) | ||||
| Accumulated other comprehensive loss | (4,391 | ) | (4,502 | ) | ||||
| Total stockholders’ equity | 213,972 | 189,298 | ||||||
| Total liabilities and stockholders’ equity | $ | 591,850 | $ | 544,782 | ||||
| TIVITY HEALTH, INC. | |||||||||
| CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) | |||||||||
| (In thousands, except earnings (loss) per share data) | |||||||||
| (Unaudited) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2017 | 2016 | ||||||||
| Revenues | $ | 140,970 | $ | 126,012 | |||||
| Cost of services (exclusive of depreciation and amortization of $657 and $1,530, respectively, included below) | 102,399 | 91,377 | |||||||
| Selling, general & administrative expenses | 8,361 | 9,411 | |||||||
| Depreciation and amortization | 787 | 1,872 | |||||||
| Restructuring and related charges | 737 | 39 | |||||||
| Operating income | 28,686 | 23,313 | |||||||
| Interest expense | 3,834 | 4,105 | |||||||
| Income before income taxes | 24,852 | 19,208 | |||||||
| Income tax expense | 9,371 | — | |||||||
| Net income from continuing operations | 15,481 | 19,208 | |||||||
| Loss from discontinued operations, net of income tax benefit | (220 | ) | (33,105 | ) | |||||
| Net income (loss) | 15,261 | (13,897 | ) | ||||||
| Less: net income (loss) attributable to non-controlling interest | — | 312 | |||||||
| Net income (loss) attributable to Tivity Health, Inc. | $ | 15,261 | $ | (14,209 | ) | ||||
| Earnings (loss) per share attributable to Tivity Health, Inc. – basic: | |||||||||
| Continuing operations | $ | 0.40 | $ | 0.53 | |||||
| Discontinued operations | $ | (0.01 | ) | $ | (0.93 | ) | |||
| Net income (loss) (1) | $ | 0.39 | $ | (0.39 | ) | ||||
| Earnings (loss) per share attributable to Tivity Health, Inc. – diluted: | |||||||||
| Continuing operations | $ | 0.38 | $ | 0.52 | |||||
| Discontinued operations | $ | (0.01 | ) | $ | (0.91 | ) | |||
| Net income (loss) (1) | $ | 0.38 | $ | (0.39 | ) | ||||
| Comprehensive income (loss) | $ | 15,372 | $ | (12,851 | ) | ||||
| Weighted average common shares | |||||||||
| and equivalents: | |||||||||
| Basic | 39,069 | 36,109 | |||||||
| Diluted | 40,541 | 36,861 | |||||||
| (1) Figures may not add due to rounding. | |||||||||
| TIVITY HEALTH, INC. | |||||||||
| CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||
| (In thousands) | |||||||||
| (Unaudited) | |||||||||
| Three Months Ended March 31, |
|||||||||
| 2017 | 2016 | ||||||||
| Cash flows from operating activities: | |||||||||
| Net income from continuing operations | $ | 15,481 | $ | 19,208 | |||||
| Net loss from discontinued operations | (220 | ) | (33,105 | ) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities, net of business acquisitions: | |||||||||
| Depreciation and amortization | 793 | 12,746 | |||||||
| Amortization of deferred loan costs | 516 | 554 | |||||||
| Amortization of debt discount | 1,931 | 1,826 | |||||||
| Share-based employee compensation expense | 1,446 | 2,427 | |||||||
| Loss on sale of TPHS business | 310 | — | |||||||
| Equity in income from joint ventures | — | (132 | ) | ||||||
| Deferred income taxes | 8,972 | (191 | ) | ||||||
| (Increase) decrease in accounts receivable, net | (16,459 | ) | 7,471 | ||||||
| (Increase) decrease in other current assets | (441 | ) | 1,955 | ||||||
| Increase (decrease) in accounts payable | 1,337 | (1,175 | ) | ||||||
| Decrease in accrued salaries and benefits | (11,773 | ) | (227 | ) | |||||
| Increase (decrease) in other current liabilities | 4,960 | (2,013 | ) | ||||||
| Other | (3,829 | ) | (1,734 | ) | |||||
| Net cash flows provided by operating activities | $ | 3,024 | $ | 7,610 | |||||
| Cash flows from investing activities: | |||||||||
| Acquisition of property and equipment | $ | (1,234 | ) | $ | (6,450 | ) | |||
| Investment in joint ventures | — | (453 | ) | ||||||
| Other | — | (275 | ) | ||||||
| Net cash flows used in investing activities | $ | (1,234 | ) | $ | (7,178 | ) | |||
| Cash flows from financing activities: | |||||||||
| Proceeds from issuance of long-term debt | 109,975 | 131,500 | |||||||
| Payments of long-term debt | (115,465 | ) | (136,084 | ) | |||||
| Payments related to tax withholding for share-based compensation | (885 | ) | (213 | ) | |||||
| Exercise of stock options | 2,250 | — | |||||||
| Change in cash overdraft and other | 1,155 | 4,600 | |||||||
| Net cash flows used in financing activities | $ | (2,970 | ) | $ | (197 | ) | |||
| Effect of exchange rate changes on cash | $ | 242 | $ | 989 | |||||
| Less: net increase in discontinued operations cash and cash equivalents | $ | — | $ | 588 | |||||
| Net (decrease) increase in cash and cash equivalents | $ | (938 | ) | $ | 636 | ||||
| Cash and cash equivalents, beginning of period | 1,602 | 233 | |||||||
| Cash and cash equivalents, end of period | $ | 664 | $ | 869 | |||||
| TIVITY HEALTH, INC. | |||||||||||||||
| RECONCILIATION OF NON-GAAP MEASURES TO GAAP MEASURES |
|||||||||||||||
| (Unaudited) | |||||||||||||||
| Reconciliation of Adjusted Net Income from Continuing Operations, Non-GAAP Basis and | |||||||||||||||
| Adjusted Net Income from Continuing Operations Per Share, Non-GAAP Basis to | |||||||||||||||
| Net Income from Continuing Operations, GAAP Basis and | |||||||||||||||
| Net Income from Continuing Operations Per Share, GAAP Basis | |||||||||||||||
| Three Months Ended March 31, 2017 |
Three Months Ended March 31, 2016 |
||||||||||||||
| $ in thousands | Per Share | $ in thousands | Per Share | ||||||||||||
| Adjusted net income from continuing operations, non-GAAP basis (1) | $ | 16,917 | $ | 0.42 | $ | 19,232 | $ | 0.52 | |||||||
| Net loss attributable to business separation expenses (2) | (991 | ) | (0.02 | ) | — | — | |||||||||
| Net loss attributable to restructuring charges (3) | (445 | ) | (0.01 | ) | (24 | ) | (0.00 | ) | |||||||
| Net income from continuing operations, GAAP basis (4) | $ | 15,481 | $ | 0.38 | $ | 19,208 | 0.52 |
|
|||||||
(1) Adjusted net income from continuing operations and adjusted net income from continuing operations per share are non-GAAP financial measures. The Company excludes net loss attributable to business separation expenses and restructuring charges from these measures because of their comparability to the Company’s historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. You should not consider adjusted net income from continuing operations and adjusted net income from continuing operations per share in isolation or as a substitute for net income from continuing operations or net income from continuing operations per share determined in accordance with accounting principles generally accepted in the United States.
(2) Net loss attributable to business separation costs consists of pre-tax charges of $1,639,000 for the three months ended March 31, 2017 related to the separation of the Network Solutions business from the disposed total population health business. The tax rate applied to these costs was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(3) Net loss attributable to restructuring charges consists of pre-tax charges of $737,000 for the three months ended March 31, 2017 associated with the 2016 restructuring of corporate support infrastructure and pre-tax charges of $39,000 for the three months ended March 31, 2016 associated with a reorganization and cost rationalization plan. The tax rate applied to these restructuring charges was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(4) Figures may not add due to rounding.
| Reconciliation of Adjusted EBITDA from Continuing Operations, Non-GAAP Basis |
||||||||||||||||
| to Net Income from Continuing Operations, GAAP Basis |
||||||||||||||||
| (In thousands) | ||||||||||||||||
| Three Months Ended March 31, 2017 |
Three Months Ended March 31, 2016 |
|||||||||||||||
| $ in thousands | % of Revenue | $ in thousands | % of Revenue | |||||||||||||
| Adjusted EBITDA from continuing operations, non-GAAP basis (5) | $ | 31,849 | 22.6 | % | $ | 25,224 | 20.0 | % | ||||||||
| Business separation costs (6) | (1,639 | ) | — | |||||||||||||
| Restructuring charges (7) | (737 | ) | (39 | ) | ||||||||||||
| EBITDA from continuing operations, non-GAAP basis (8) | 29,473 | 25,185 | ||||||||||||||
| Depreciation and amortization | (787 | ) | (1,872 | ) | ||||||||||||
| Interest expense | (3,834 | ) | (4,105 | ) | ||||||||||||
| Income tax expense | (9,371 | ) | — | |||||||||||||
| Net income from continuing operations, GAAP basis | $ | 15,481 | $ | 19,208 | ||||||||||||
(5) Adjusted EBITDA from continuing operations is a non-GAAP financial measure. The Company excludes business separation costs and restructuring charges from this measure because of its comparability to the Company’s historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. You should not consider Adjusted EBITDA from continuing operations in isolation or as a substitute for net income from continuing operations determined in accordance with accounting principles generally accepted in the United States.
(6) Business separation costs consists of pre-tax charges related to the separation of the Network Solutions business from the disposed total population health business.
(7) Restructuring charges for the three months ended March 31, 2017 consists of pre-tax charges associated with the 2016 restructuring of corporate support infrastructure. Restructuring charges for the three months ended March 31, 2016 consists of pre-tax charges associated with a reorganization and cost rationalization plan.
(8) EBITDA from continuing operations is a non-GAAP financial measure. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. You should not consider EBITDA from continuing operations in isolation or as a substitute for net income from continuing operations determined in accordance with accounting principles generally accepted in the United States.
| Reconciliation of Adjusted Net Income from Continuing Operations | ||||
| Per Share (“EPS”) Guidance, Non-GAAP Basis to EPS Guidance, GAAP Basis | ||||
| Fiscal Year Ending December 31, 2017 |
||||
| Adjusted EPS guidance, non-GAAP basis (9) | $ | 1.50 – 1.58 | ||
| EPS (loss) guidance attributable to business separation costs (10) | (0.02 | ) | ||
| EPS (loss) guidance attributable to restructuring charges (11) | (0.01 | ) | ||
| EPS guidance, GAAP basis | $ | 1.47 – 1.55 | ||
(9) Adjusted EPS guidance is a non-GAAP financial measure. The Company excludes EPS (loss) guidance attributable to business separation expenses and restructuring charges from this measure because of its comparability to the Company’s historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider adjusted EPS guidance in isolation or as a substitute for EPS guidance determined in accordance with accounting principles generally accepted in the United States.
(10) EPS (loss) guidance attributable to business separation costs consists of pre-tax charges of $1,639,000 related to the separation of the Network Solutions business from the disposed total population health business. The tax rate applied to these costs was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(11) EPS (loss) guidance attributable to restructuring charges consists of pre-tax charges of $737,000 associated with the 2016 restructuring of corporate support infrastructure. The tax rate applied to these restructuring charges was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
CONTACT: Investor Relations Contact: Chip Wochomurka (615) 614-4493 [email protected]